At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 24 enrolled
Drug / intervention
Placebo Oral Tablet +1 moredrug
Likely dose
Naltrexone 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Defining an Endopheneotype for Alcohol Treatment With Naltrexone
In Brief
A Phase 4 clinical trial evaluating Placebo Oral Tablet and Naltrexone for Alcoholism. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This is a study involving treatment for alcohol dependence among males of European or Asian decent. The ultimate aim of this line of investigation is to further establish a genetic link between alcohol dependence and treatment by defining an endophenotype associated with treatment response. The study consists of two inpatient alcohol challenge sessions with treatment using random assignment to either naltrexone or placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcoholism
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedJan 2009
Primary CompletionApr 2010
Study CompletionJun 2010
TodayJul 2026
First PostedJan 6, 2009
Enrollment StartDec 1, 2007
Primary CompletionApr 1, 2010
Study CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.5 years ago
Interventions
Placebo Oral Tabletdrug
Placebo pill
Naltrexonedrug
50 mg of naltrexone prior to challenge session